DGAP-Adhoc: ELANIX BIOTECHNOLOGIES AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD Biotechnologies AG:
DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Legal Matter ELANIX BIOTECHNOLOGIES AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD Frankfurt, 27 February 2020 - The Vice Chairman of the Supervisory Board Fang Bao and a member of the Supervisory Board, Prof. Zhanfeng Cui notified the CEO that they resigned from the office due to work commitments. The District Court in Berlin has appointed successors, following the Board's proposal of two suitable candidates. The Supervisory Board of Elanix Biotechnologies AG ("Company", "Elanix") has nominated by juridical order Marco Christen and Yves Bonnard to become members of the Supervisory Board with immediate effect. Today, the Supervisory Board of Elanix has re-elected Anja Silling to remain the Chairman of the Board and Marco Christen, to be the Vice Chairman. Lee-Ann Laurent-Applegate
27-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Elanix Biotechnologies AG |
c/o Frankfurt, Hanauer Landstrasse 291 B (BC GmbH) | |
60314 Frankfurt am Main | |
Germany | |
Internet: | www.elanixbiotechnologies.ch |
ISIN: | DE000A0WMJQ4 |
WKN: | A0WMJQ |
Listed: | Regulated Market in Frankfurt (General Standard) |
EQS News ID: | 984999 |
End of Announcement | DGAP News Service |
|
984999 27-Feb-2020 CET/CEST